These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Comparable glucagon-stimulated amino acid suppression in individuals with and without hepatic steatosis or steatohepatitis. Heebøll S; Wegener G; Grønbæk H; Nielsen S Am J Physiol Endocrinol Metab; 2024 Sep; ():. PubMed ID: 39291967 [TBL] [Abstract][Full Text] [Related]
10. Determinants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study. Winther-Sørensen M; Garcia SL; Bartholdy A; Ottenheijm ME; Banasik K; Brunak S; Sørensen CM; Gluud LL; Knop FK; Holst JJ; Rosenkilde MM; Jensen MK; Wewer Albrechtsen NJ Diabetologia; 2024 Aug; 67(8):1602-1615. PubMed ID: 38705923 [TBL] [Abstract][Full Text] [Related]
11. Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. Demant M; Bagger JI; Suppli MP; Lund A; Gyldenløve M; Hansen KB; Hare KJ; Christensen M; Sonne DP; Holst JJ; Vilsbøll T; Knop FK Metab Syndr Relat Disord; 2018 Dec; 16(10):530-536. PubMed ID: 30325692 [TBL] [Abstract][Full Text] [Related]
12. Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Scavo MP; Lisco G; Depalo N; Rizzi F; Volpe S; Arrè V; Carrieri L; Notarnicola M; De Nunzio V; Curri ML; De Pergola G; Piazzolla G; Giannelli G Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338770 [TBL] [Abstract][Full Text] [Related]
13. Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen. Sharma A; Godina Leiva E; Kalavalapalli S; Lomonaco R; Marangi SA; Valdez Saenz E; Gonzalez MA; Ortiz Rocha A; Cuervo Pardo N; Rosenberg J; Bedossa P; Bril F; Barb D; Cusi K Obesity (Silver Spring); 2024 Oct; 32(10):1967-1974. PubMed ID: 39315409 [TBL] [Abstract][Full Text] [Related]
14. Weight-adjusted waist index is positively and linearly associated with all-cause and cardiovascular mortality in metabolic dysfunction-associated steatotic liver disease: findings from NHANES 1999-2018. Liu W; Yang X; Zhan T; Huang M; Tian X; Tian X; Huang X Front Endocrinol (Lausanne); 2024; 15():1457869. PubMed ID: 39403588 [TBL] [Abstract][Full Text] [Related]
15. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan. Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965 [TBL] [Abstract][Full Text] [Related]
16. Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes. Al-Ozairi E; Irshad M; AlKandari J; Mashankar A; Alroudhan D; le Roux CW Diabetes Obes Metab; 2024 Sep; 26(9):4052-4059. PubMed ID: 38984381 [TBL] [Abstract][Full Text] [Related]
17. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). ; ; Obes Facts; 2024; 17(4):374-444. PubMed ID: 38852583 [TBL] [Abstract][Full Text] [Related]
18. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus. Mantovani A; Morieri ML; Aldigeri R; Palmisano L; Masulli M; Bonomo K; Baroni MG; Cossu E; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Cas AD; de Kreutzenberg SV; Targher G Diabetes Metab; 2024 Jan; 50(1):101497. PubMed ID: 37992857 [TBL] [Abstract][Full Text] [Related]
19. Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence. McGlone ER; Bloom SR; Tan TM J Endocrinol; 2024 Jun; 261(3):. PubMed ID: 38579751 [TBL] [Abstract][Full Text] [Related]
20. Metabolic Dysfunction-Associated Steatotic Liver Disease in Severe Obesity and Concordance between Invasive (Biopsy) and Noninvasive (OWLiver®) Diagnoses. Navarro-Masip È; Mestres Petit N; Salinas-Roca B; Herrerías F; Vilardell F; de la Fuente MC; Pallares J; Santamaría M; Zorzano-Martínez M; Sánchez E; Matías-Guiu X; López-Cano C; Soler AG; León-Mengíbar J; Bueno M; Lecube A Obes Facts; 2024; 17(5):473-482. PubMed ID: 38934179 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]